# EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma

> **NCT00001563** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 39 (actual)

## Conditions studied

- AIDS Related Lymphoma
- AIDS-Associated Lymphoma

## Interventions

- **BIOLOGICAL:** Filgrastim
- **BIOLOGICAL:** Rituximab
- **DRUG:** EPOCH

## Key facts

- **NCT ID:** NCT00001563
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-01-08
- **Primary completion:** 2005-05-05
- **Final completion:** 2005-05-05
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2022-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001563, "EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00001563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*